Tilray (NASDAQ:TLRY) Misses Q1 Revenue Estimates

Cannabis company Tilray Brands (NASDAQ:TLRY) fell short of the market’s revenue expectations in Q1 CY2025, with sales falling 1.4% year on year to $185.8 million. The company’s full-year revenue guidance of $875 million at the midpoint came in 2% below analysts’ estimates. Its non-GAAP loss of $0 per share was significantly above analysts’ consensus estimates.

Is now the time to buy Tilray? Find out in our full research report .

Tilray (TLRY) Q1 CY2025 Highlights:

Irwin D. Simon, Chairman and Chief Executive Officer of Tilray Brands, stated, "Tilray Brands is shaping the future of consumer markets with a robust global infrastructure spanning the beverage, cannabis, and wellness industries. We are meeting the needs of today’s consumers while preparing for the demands of tomorrow. In the third quarter, we prioritized sales quality and revenue, protected margins, reduced debt, and improved our capital structure. With a strong balance sheet and a clear vision for the future, Tilray is well positioned to capitalize on emerging opportunities and ensure long-term success.”

Company Overview

Founded in 2013, Tilray Brands (NASDAQ:TLRY) engages in cannabis research, cultivation, and distribution, offering a range of medical and recreational cannabis products, hemp-based foods, and alcoholic beverages.

Beverages, Alcohol, and Tobacco

These companies' performance is influenced by brand strength, marketing strategies, and shifts in consumer preferences. Changing consumption patterns are particularly relevant and can be seen in the rise of cannabis, craft beer, and vaping or the steady decline of soda and cigarettes. Companies that spend on innovation to meet consumers where they are with regards to trends can reap huge demand benefits while those who ignore trends can see stagnant volumes. Finally, with the advent of the social media, the cost of starting a brand from scratch is much lower, meaning that new entrants can chip away at the market shares of established players.

OK